Prakiraan wutah bathi kanggo taun ngarep China Pharma Holdings, Inc. (CPHI)

The forward EPS growth vector for next year on GURU.Markets demonstrates a trend where 0.00 forms the current metric value. China Pharma Holdings (CPHI) is expanding its portfolio of gastrointestinal and central nervous system drugs, leveraging PRC government procurement. However, the business remains dependent on external suppliers of active pharmaceutical ingredients. Meanwhile, management is maintaining a cautious tactical approach, adapting internal processes to the country's medical reforms.
China Pharma Holdings Inc. - rincian analitis lan metrik utama (CPHI)

This indicator measures the consensus forecast for earnings per share changes, reflecting market expectations regarding the business's ability to generate future income. By analyzing the expected EPS change for the coming year, an investor can identify the risk of margin degradation for China Pharma Holdings (CPHI), which is further evidenced by the current working capital deficit and declining drug sales in the domestic market.